Key facts
- What counts as a weight-loss peptide: short chains of amino acids that mimic gut, pancreatic or pituitary hormones controlling appetite and fuel use.
- Approved in the US for weight management: liraglutide (Saxenda), semaglutide (Wegovy) and tirzepatide (Zepbound). All injectable, all prescription-only.
- Investigational: retatrutide and cagrilintide-plus-semaglutide are in late-stage trials and are not approved anywhere.
- Thin or animal-only evidence: AOD9604, HGH fragment 176-191, MOTS-c, and most peptide fat-burner blends.
- Not a weight-loss drug: tesamorelin, approved only for HIV-associated visceral fat, cut visceral fat without changing total body weight.
- Most common trial side effects: nausea, diarrhea, vomiting and constipation, worst during dose escalation.
- Legal status: no peptide with meaningful weight-loss evidence can be legally sold to consumers without a prescription in the US, UK, EU or Australia.
What are peptides for weight loss?
A peptide is a short chain of amino acids — long enough to act like a hormone, short enough to be manufactured synthetically. The peptides that matter for body weight are copies or modifications of hormones your gut, pancreas and pituitary already release to tell the brain how much fuel is on board.
The 21st century rewrote appetite physiology around these molecules. Glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), amylin, glucagon and ghrelin all turned out to be tractable drug targets, and mapping how they regulate hunger and energy expenditure is what made the current generation of obesity drugs possible (PMID 34067710). GLP-1 itself slows gastric emptying, amplifies glucose-dependent insulin release and reduces food intake through receptors in the hypothalamus and brainstem (PMID 17928588).
Native GLP-1 is useless as a drug because enzymes destroy it in about two minutes. The engineering problem of the last two decades was making an analogue that survives long enough to dose weekly, which is why modern GLP-1 receptor agonists carry fatty-acid chains and amino-acid substitutions that resist degradation and bind albumin (PMID 31050435). It is also why almost all of them are injected: peptides are torn apart by gut enzymes and struggle to cross the intestinal wall intact (PMID 15984901).
That distinction matters commercially. "Peptide" is not a category of efficacy — it is a category of chemistry. Wegovy and a vial of AOD9604 from an overseas website are both peptides. Only one of them has a phase 3 outcome dataset behind it. Our explainer on GLP-1 receptor agonists covers the mechanism in more depth.
Do peptides for weight loss actually work?
Some do, dramatically. Most of the ones marketed online do not.
The honest version of the answer splits into three groups. First, peptides that have completed randomized, placebo-controlled phase 3 trials with body weight as the primary endpoint and are approved by regulators — semaglutide, tirzepatide, liraglutide. Second, peptides in active late-stage development whose published phase 2 results are strong but whose approval and long-term safety are unresolved — retatrutide, cagrilintide combinations. Third, everything else: molecules with an interesting mechanism, an animal study, and a supplement industry built on top of them.
The size of the gap between group one and group three is easy to underrate. Obesity pharmacology has an unusually long graveyard of compounds that looked promising in rodents and either failed in humans or were withdrawn for safety (PMID 23092275). Mechanistic plausibility has repeatedly failed to predict clinical results in this field, which is exactly why "it increases lipolysis in adipocytes" is not evidence that a peptide will make a person lose weight.
Evidence tiers: every weight-loss peptide compared
The table below is the fastest way to see where each molecule actually sits. Percentages are mean changes from baseline in the trial's primary analysis, not what any individual should expect.
| Peptide | Target | Best human evidence | Status | Mean weight change in trial |
|---|---|---|---|---|
| Tirzepatide | GIP + GLP-1 | SURMOUNT-1, 72 weeks, n=2,539 | FDA approved (Zepbound) | −15.0% to −20.9% vs −3.1% placebo |
| Semaglutide 2.4 mg | GLP-1 | STEP 1, 68 weeks, n=1,961 | FDA approved (Wegovy) | −14.9% vs −2.4% placebo |
| Liraglutide 3.0 mg | GLP-1 | SCALE, 56 weeks, n=3,731 | FDA approved (Saxenda) | −8.0% vs −2.6% placebo |
| Retatrutide | GIP + GLP-1 + glucagon | Phase 2, 48 weeks, n=338 | Investigational, not approved | −24.2% at highest dose vs −2.1% placebo |
| Cagrilintide + semaglutide | Amylin + GLP-1 | REDEFINE 1, 68 weeks, n=3,417 | Investigational, not approved | −20.4% vs −3.0% placebo |
| Tesamorelin | GHRH analogue | Two 26-week HIV lipodystrophy trials | Approved only for HIV visceral fat | Visceral fat −15%; total body weight largely unchanged |
| AOD9604 | hGH 177-191 fragment | Rodent lipid metabolism studies | Not approved for obesity anywhere | No approved-standard human efficacy result |
| MOTS-c | Mitochondrial-derived peptide | Observational human plasma studies | Research compound only | No randomized weight-loss trial |
| HGH fragment 176-191 / lipotropic blends | Mixed or undefined | None of adequate quality | Unapproved, sold as research chemicals | No credible controlled data |
Tier 1: approved drugs with phase 3 data
Semaglutide
STEP 1 randomized 1,961 adults with overweight or obesity to weekly semaglutide 2.4 mg or placebo alongside lifestyle intervention. At week 68 the semaglutide group had lost a mean 14.9% of body weight versus 2.4% on placebo, and roughly a third exceeded 20% loss (PMID 33567185). That result is the reference point every newer molecule is measured against. Full detail sits in our semaglutide research summary.
Tirzepatide
Tirzepatide adds GIP receptor agonism to GLP-1. In SURMOUNT-1, 2,539 adults without diabetes received weekly tirzepatide at 5, 10 or 15 mg or placebo for 72 weeks; mean weight reductions were 15.0%, 19.5% and 20.9% against 3.1% for placebo (PMID 35658024). In people who also had type 2 diabetes — historically a harder population to move — SURMOUNT-2 still produced 12.8% and 14.7% reductions (PMID 37385275). The head-to-head trial SURMOUNT-5 compared the two directly and found 20.2% loss with tirzepatide versus 13.7% with semaglutide at 72 weeks (PMID 40353578). See tirzepatide and the tirzepatide vs semaglutide comparison.
Liraglutide
The oldest of the three and the weakest performer. The SCALE trial found a mean 8.0% weight reduction at 56 weeks with daily liraglutide 3.0 mg versus 2.6% on placebo (PMID 26132939). Critical reviews have noted the modest effect size relative to cost and the daily injection burden (PMID 28392927). It is still clinically useful, but it explains why weekly agents took the market. Head-to-head comparisons across the class are reviewed in PMID 33767808. More in our liraglutide page.
Tier 2: investigational peptides still in trials
Retatrutide
Retatrutide hits three receptors — GIP, GLP-1 and glucagon — with the glucagon arm intended to raise energy expenditure rather than only suppress intake. Its phase 2 obesity trial reported a mean 24.2% weight reduction at 48 weeks at the highest dose studied, against 2.1% for placebo (PMID 37366315). Parallel phase 2 work in type 2 diabetes (PMID 37385280) and in metabolic dysfunction-associated steatotic liver disease (PMID 38858523) showed large reductions in liver fat.
Two caveats get lost when those numbers circulate on social media. Phase 2 results routinely shrink in phase 3, and retatrutide is not approved by any regulator — which means the vials being sold online under that name are unapproved copies of an unlicensed investigational drug of unverified content. Our retatrutide summary handles the trial data in full.
Cagrilintide and CagriSema
Cagrilintide is a long-acting amylin analogue. Amylin is co-secreted with insulin and contributes a satiety signal that operates partly independently of GLP-1, so combining the two is an attempt at additive appetite suppression. In REDEFINE 1, weekly coadministered cagrilintide and semaglutide produced a mean 20.4% weight reduction at 68 weeks versus 3.0% on placebo (PMID 40544433). Still not approved. See cagrilintide.
Tier 3: sold for fat loss, thin human evidence
AOD9604 and HGH fragment 176-191
AOD9604 is a synthetic fragment of the C-terminal region of human growth hormone, designed to keep the lipolytic activity of GH without the effects on blood glucose or IGF-1. The foundational work showed reduced body weight and increased fat oxidation in obese mice (PMID 11713213). It reached human obesity trials in the 2000s and was never approved for obesity in any jurisdiction — the program did not produce a marketable efficacy result. It is now sold as a research chemical and as an unapproved cosmetic or supplement ingredient. Read the detail on AOD9604.
MOTS-c
MOTS-c is a peptide encoded in mitochondrial DNA with genuinely interesting biology in metabolic regulation and exercise response (PMID 36761202). Human data is observational: plasma MOTS-c concentrations correlated with insulin sensitivity in lean but not obese individuals (PMID 29593067). A correlation in lean people is not a fat-loss treatment. No randomized trial has tested administered MOTS-c for weight loss in humans. See MOTS-c.
Tesamorelin
Tesamorelin is the strongest case of a peptide whose evidence is real but routinely misrepresented. It is a growth hormone-releasing hormone analogue approved specifically to reduce excess abdominal fat in HIV-associated lipodystrophy. In its registration trials it reduced visceral adipose tissue by roughly 15% over 26 weeks without a meaningful change in total body weight (PMID 20554713), and a later study confirmed reductions in visceral and liver fat in the same population (PMID 25038357). Selective fat redistribution in one clinical population is not general obesity treatment. Details on our tesamorelin page.
Lipotropic blends and everything else
Compounded "lipo" injections generally contain methionine, inositol, choline and B vitamins, sometimes with a peptide added for marketing weight. There is no adequately powered randomized evidence that these produce clinically meaningful weight loss. The same applies to the repair and recovery peptides frequently upsold alongside fat-loss protocols — reviews of BPC-157 note that human clinical evidence remains scarce and that unregulated product quality is a distinct hazard from the molecule itself (PMID 40789979).
How fast do weight-loss peptides work?
Faster than most people expect on appetite, slower than most people expect on the scale. Participants in the GLP-1 trials generally noticed reduced hunger and earlier fullness within the first few weeks of starting, but the weight-loss curves in STEP 1 and SURMOUNT-1 did not flatten until well past the one-year mark. STEP 1 ran 68 weeks; SURMOUNT-1 ran 72. Dose escalation is deliberately slow to limit nausea, so early weeks are spent below the dose that produced the headline result.
The other half of the timing question is what happens when treatment stops. In the STEP 1 extension, participants who came off semaglutide regained roughly two thirds of the weight they had lost within a year, and the improvements in blood pressure, lipids and glycemic markers moved back toward baseline (PMID 35441470). This is the most important single fact about the class and the one least represented in marketing.
Side effects reported in the trials
Gastrointestinal effects dominate every trial in this class: nausea, diarrhea, vomiting and constipation, typically mild to moderate, most intense during dose escalation, and generally easing as the dose stabilizes. In STEP 1, GI events led about 4.5% of the semaglutide group to discontinue, versus 0.8% on placebo (PMID 33567185). SURMOUNT-1 reported a similar pattern for tirzepatide (PMID 35658024).
Less common but clinically significant issues discussed in the labels and literature include gallbladder events during rapid weight loss, pancreatitis, and a contraindication in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, based on rodent C-cell findings. Reviews of the class collate the comparative tolerability data across agents (PMID 33767808).
Unapproved peptides carry a different risk profile entirely, because the risk is unquantified. The instructive precedent is melanotan-2, a peptide sold online for years before case reports linked unregulated use to melanoma diagnoses, rhabdomyolysis and other harms (PMID 28266027). Absence of reported side effects for a research chemical usually reflects absence of surveillance, not safety.
Are weight-loss peptides legal?
Every peptide with credible weight-loss evidence is a prescription-only medicine in the United States, United Kingdom, European Union and Australia. There is no legal consumer channel for them outside a prescription. Retatrutide and cagrilintide are not approved anywhere, which places them outside even that channel.
The grey market works around this with labeling. Vials marked "research use only" or "not for human consumption" are sold without any of the identity, purity, sterility or dose-accuracy controls applied to a licensed medicine. The FDA has separately warned about unapproved and compounded GLP-1 products, including dosing errors and products using salt forms such as semaglutide sodium that are not the ingredient studied in the trials. Several research peptides — including MOTS-c and BPC-157 — have been placed in Category 2 of the FDA's interim 503A bulk substances list, meaning the agency identified significant safety risks for use in compounding. Our guide to peptide legality breaks the rules down by country.
What is worth tracking if you are prescribed one
If a clinician has put you on one of the approved drugs, the variables that actually inform the next appointment are unglamorous: the date of each weekly injection, which site was used, the titration step you are on and when it changed, side effects and their timing relative to the dose, weight trend over months rather than days, and food and activity patterns as appetite shifts. Titration decisions are clinical calls made on that history — which means the history has to exist and be accurate.
Most people try to hold this in memory or a notes app and lose the thread by month three, which is exactly when the data becomes useful. A structured log is the difference between "I think the nausea was worse after the increase" and a dated record your prescriber can read in ten seconds. Our guide on how to track peptides and medications covers the mechanics.
Frequently asked questions
What is the most effective peptide for weight loss?
Among approved drugs, tirzepatide has produced the largest average weight loss in head-to-head research. In SURMOUNT-5, participants on tirzepatide lost 20.2% of body weight at 72 weeks versus 13.7% on semaglutide. Retatrutide produced a larger figure still in a 48-week phase 2 trial, but it is investigational and not approved anywhere. Individual results vary widely and none of these are self-prescribed.
Can you buy peptides for weight loss without a prescription?
Not legally as a medicine. Every peptide with real weight-loss evidence is a prescription drug in the United States, the UK, the EU and Australia. Websites that sell vials labeled research chemical or not for human consumption are exploiting a labeling loophole, not a legal route to treatment. Those products are not tested for identity, purity, sterility or dose accuracy.
Do peptides like BPC-157, ipamorelin or CJC-1295 cause weight loss?
There is no controlled human trial showing that BPC-157, ipamorelin or CJC-1295 causes meaningful fat loss. Growth hormone secretagogues raise growth hormone and IGF-1, which has modest effects on body composition in deficiency states, but that is not the same as weight loss in obesity. BPC-157 human evidence is essentially absent outside small early-stage work.
How long do weight-loss peptides take to work?
In the major trials, appetite changes appeared within the first weeks and measurable weight loss within the first two to three months, but the curves did not flatten until roughly month 12 to 18. STEP 1 ran 68 weeks and SURMOUNT-1 ran 72 weeks. Reading a four-week result as a plateau is the single most common misreading of this data.
What happens if you stop taking a weight-loss peptide?
Weight usually comes back. In the STEP 1 extension, participants who stopped semaglutide regained about two thirds of their lost weight within a year, and cardiometabolic improvements reverted toward baseline. These drugs treat a chronic condition rather than cure it, which is why clinicians frame them as long-term therapy rather than a course you finish.
Is AOD9604 proven to burn fat in humans?
No. AOD9604 is a fragment of human growth hormone studied for lipolysis, and the persuasive fat-loss results come from rodent work. It was taken into human obesity trials in the 2000s and was never approved for obesity anywhere. It is sold today as a research chemical and as an unapproved ingredient, not as a proven treatment.
Is compounded semaglutide the same as Wegovy or Ozempic?
No. Compounded and grey-market versions are not reviewed by the FDA for safety, effectiveness or quality, and salt forms such as semaglutide sodium are not the same active ingredient studied in the trials. The FDA has warned about dosing errors and adverse events tied to unapproved GLP-1 products. Only the branded pens carry the clinical dataset described on this page.
Do weight-loss peptides cause muscle loss?
Some lean mass is lost alongside fat, as with any substantial weight loss. Body composition substudies of GLP-1 based drugs show that fat mass accounts for the majority of the reduction, but lean mass falls too. This is why trial protocols pair the drug with a calorie deficit plus physical activity, and why resistance training and protein intake come up in every clinical discussion of these medications.
Does tesamorelin work for general weight loss?
It is approved only to reduce excess abdominal fat in HIV-associated lipodystrophy, and in those trials it cut visceral adipose tissue by roughly 15% without meaningfully changing total body weight. That is a fat redistribution effect in a specific patient group, not a general obesity treatment, and it has never been approved for weight loss in the general population.
Are lipotropic or fat-burner peptide blends worth it?
Blends marketed as lipotropic injections usually combine vitamins and amino acids such as methionine, inositol and choline, sometimes with a peptide added. There are no adequately powered randomized trials showing they produce clinically meaningful weight loss. The peptide name on the label is doing marketing work rather than evidentiary work.
Sources
Every claim above traces to peer-reviewed literature indexed on PubMed:
- Once-Weekly Semaglutide in Adults with Overweight or Obesity — PubMed 33567185
- Tirzepatide Once Weekly for the Treatment of Obesity — PubMed 35658024
- Tirzepatide once weekly for obesity in people with type 2 diabetes — PubMed 37385275
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity — PubMed 40353578
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management — PubMed 26132939
- Liraglutide for weight management: a critical review of the evidence — PubMed 28392927
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — PubMed 37366315
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes — PubMed 37385280
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease — PubMed 38858523
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity — PubMed 40544433
- Weight regain and cardiometabolic effects after withdrawal of semaglutide — PubMed 35441470
- GLP-1 receptor agonists: an updated review of head-to-head clinical studies — PubMed 33767808
- The physiology of glucagon-like peptide 1 — PubMed 17928588
- Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency — PubMed 31050435
- The Role of Peptide Hormones Discovered in the 21st Century in the Regulation of Appetite and Metabolism — PubMed 34067710
- Oral delivery of peptide drugs: barriers and developments — PubMed 15984901
- Obesity pharmacotherapy: current perspectives and future directions — PubMed 23092275
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism — PubMed 11713213
- Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation — PubMed 20554713
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients — PubMed 25038357
- MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation — PubMed 36761202
- Plasma MOTS-c levels are associated with insulin sensitivity in lean but not obese individuals — PubMed 29593067
- Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues — PubMed 28266027
- Regeneration or Risk? A Narrative Review of BPC-157 — PubMed 40789979